You can buy or sell BioMarin and other stocks, options, ETFs, and crypto commission-free!
BioMarin Pharmaceutical Inc. Common Stock, also called BioMarin, is a biotechnology company, which develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Read More Its products include Aldurazyme, Brineura, Kuvan, Naglazyme, Palynziq and Vimizim. The company was founded by Christopher M. Starr and Grant W. Denison on March 21, 1997 and is headquartered in San Rafael, CA.
San Rafael, California
52 Week High
52 Week Low
Seeking AlphaMay 22
JP Morgan likes BioMarin, sees over 50% upside on promising pipeline
Barron's reports that JPMorgan is bullish on BioMarin Pharmaceutical (BMRN -0.6% ). Analyst Cory Kasimov (Overweight/$133) is confident that the company will double revenues over the next five years.
BioMarin Stock Is a Buy, With or Without Hemophilia Treatment, J.P. Morgan Says
BioMarin Stock Is a Buy, With or Without Hemophilia Treatment, J.P. Morgan Says Gene Therapy Photograph by Jaron Nix Text size As investors wait for a key update on BioMarin Pharmaceutical ’s work on a gene therapy to treat hemophilia A, one analyst said the firm is in strong shape, even if the gene-therapy results are disappointing. Cory Kasimov at J.P. Morgan wrote In a note on Wednesday that BioMarin (ticker: BMRN) is undervalued. Although he doesn’t dispute that shares could fall if the gene-therapy...
Yahoo FinanceMay 16
BioMarin in Focus: Stock Moves 7.5% Higher
BioMarin Pharmaceutical Inc. BMRN was a big mover last session, as the company saw its shares rise nearly 8% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This stock, which remained volatile and traded within the range of $80.35 –$88.51 in the past one-month time frame, witnessed a sharp increase yesterday. The company has seen seven negative estimate revisions in the past few weeks, while its Zacks Consensus Estimate for the current quarter h...
Expected Aug 1, After Hours